Downregulation of HORMAD1 in SCCs cancer cells sensitized them to etoposide treatment and may sensitize HORMAD1 dependent cells/tumors to other chemotherapy treatments, as demonstrated in studies involving breast and lung adenocarcinoma models [27,28,29]. This evidence concerns the gene HORMAD1 and lung adenocarcinoma.